tDCS therapies are now reimbursed in Estonia
Psychiatric and neuropathic patients in Estonia can now access tDCS treatments more efficiently, as the Estonian public healthcare system is currently reimbursing these neuromodulation therapies as part of its service portfolio.
With 1.3 million people, Estonia has a depression rate of about 4% (Our World in Data, 2019). After this decision, it has become the second country in Europe, after Finland, to officially support tDCS therapies as an effective tool to treat a wide range of ailments, such as depression and chronic pain.
More than ten public hospitals and private clinics offer Sooma tDCS treatments in their portfolio, including leading area hospitals and national-level clinics. But, more importantly, now healthcare professionals all around the country have one more safe, effective, and accessible treatment option to offer their patients with psychiatric or neurologic disorders.
TDCS is the treatment method offered by Sooma for depression (Sooma Depression Therapy, indicated for Major Depressive Disorder) and chronic pain (Sooma Pain Therapy, indicated for Fibromyalgia and chronic neuropathic pain). By using Sooma devices, you ensure that you are performing a safe and effective patient treatment, should be it in the hospital or at patients’ homes, with legal, regulated, tested, and effective equipment that complies with the latest EU regulations and features all the recommended elements listed on this article.
Latest news
Sooma closes 2025 with major milestones in improved access to better depression and pain care globally
Read more
FDA approved tDCS for at-home depression treatment
Read more
Science round-up webinar: tDCS in Depression and Chronic Pain – Clinical Advancements 2025
Read more